Free shipping on all orders over $ 500

Avelumab (MSB0010718C)

Cat. No. M3813
Avelumab (MSB0010718C) Structure


Size Price Availability Quantity
5mg USD 960  USD1200 In stock
10mg USD 1568  USD1960 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Avelumab is a whole monoclonal antibody of isotype IgG1 that binds to the programmed death-ligand 1 (PD-L1) and therefore inhibits binding to its receptor programmed cell death 1 (PD-1). Formation of a PD-1/PD-L1 receptor/ligand complex leads to inhibition of CD8+ T cells, and therefore inhibition of an immune reaction. Immunotherapy aims at ceasing this immune blockage by blocking those receptor ligand pairs. In the case of avelumab, the formation of PD-1/PDL1 ligand pairs is blocked and CD8+ T cell immune response should be increased. PD-1 itself has also been a target for immunotherapy. Therefore, avelumab belongs to the group of immune checkpoint blockade cancer therapies. By retaining a native Fc-region, avelumab is thought to engage the innate immune system and may induce antibody-dependent cell-mediated cytotoxicity (ADCC).

Avelumab recognizes murine PD-L1

Product Citations
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 143829.40
Formula C6374H9898N1694O2010S44
CAS Number 1537032-82-8
Purity >98%
Storage -80°C for long term

[1] Jonathan K Fallon, et al. Oncotarget. Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

[2] Rika Fujii, et al. Oncotarget. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab

[3] Vandeveer AJ, et al. Cancer Immunol Res. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Related PD-1/PD-L1 Products
Human PD-L1 inhibitor V

Human PD-L1 inhibitor V is a human PD-1 protein binding peptide with a Kd value of 3.32 μM that inhibits the binding of human PD-1/PD-L1.Sequence:Leu-Asp-Tyr-Val-Asn-Arg-Arg-Lys-Met-Tyr-Gln.


ARB-272572 is a potent small molecule PD-L1 inhibitor with an IC50 value of 400 pM.


AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.


Cemiplimab (Libtayo) is a human monoclonal antibody injected intravenously that targets programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands PD-1 and PD-L2. Cemiplimab blocks T-cell inactivation and boosts the immune system's antitumor response.


CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1.

Abmole Inhibitor Catalog

Keywords: Avelumab (MSB0010718C), MSB0010718C supplier, PD-1/PD-L1, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.